- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Obesity medicine.
Displaying page 1 of 1.
EudraCT Number: 2022-001384-27 | Sponsor Protocol Number: 2022-031 | Start Date*: 2023-02-28 | |||||||||||||||||||||
Sponsor Name:Franciscus Gasthuis & Vlietland | |||||||||||||||||||||||
Full Title: Peroperative Administration of Tranexamic acid in Roux-en-Y and one-anastomosis gastric bypass to reduce hemorrhage rates (PATRY study): a randomized controlled trial | |||||||||||||||||||||||
Medical condition: Morbid obesity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006352-36 | Sponsor Protocol Number: VPN-10-18 | Start Date*: 2013-04-11 | ||||||||||||||||
Sponsor Name:Lithuanian University of Health Sciences, Endocrinology Department | ||||||||||||||||||
Full Title: Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evalua... | ||||||||||||||||||
Medical condition: The aim of our study is to establish the effectivenes and safety of metformin use in pediatric obese population; to assess the prevalence of insulin resistance, metabolic syndrome, polycystic ovary... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001859-40 | Sponsor Protocol Number: 2019-041 | Start Date*: 2020-11-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Franciscus Gasthuis & Vlietland | |||||||||||||||||||||||||||||||||
Full Title: PEROPERATIVE TRANEXAMIC ACID IN BARIATRIC FAST TRACK SURGERY TO REDUCE HEMORRAGE RATES | |||||||||||||||||||||||||||||||||
Medical condition: Morbid obesity | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002834-15 | Sponsor Protocol Number: C3991004 | Start Date*: 2023-01-31 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WI... | ||||||||||||||||||
Medical condition: Type 2 Diabetes Mellitus and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005989-34 | Sponsor Protocol Number: 034B20 | Start Date*: 2022-08-31 | |||||||||||
Sponsor Name:Aphaia Pharma AG | |||||||||||||
Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s... | |||||||||||||
Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001048-22 | Sponsor Protocol Number: 990312 | Start Date*: 2005-12-29 |
Sponsor Name:Göteborg University, Institute for Internal Medicine | ||
Full Title: Rosuvastatin in Visceral Adiposity. A 26-week, single center, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the effect of rosuvastatin on visceral adipose tissue in... | ||
Medical condition: Visceral adiposity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000570-19 | Sponsor Protocol Number: TBE_obesity_1.1 | Start Date*: 2014-07-11 |
Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine | ||
Full Title: Applikation of FSME-IMMUN® in obese persons | ||
Medical condition: Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infection. The aim of this study is to clarify if a modif... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005892-83 | Sponsor Protocol Number: WCH/2008/001 | Start Date*: 2009-01-14 |
Sponsor Name:Epsom and St Helier University Hospitals NHS Trust | ||
Full Title: Does metformin improve pregnancy outcomes [ incidence of LGA (≥90% birth weight centile) babies onset of maternal Gestational Diabetes, hypertension, PET, shoulder dystocia, admission to SCBU) in o... | ||
Medical condition: Obesity in pregnancy. Obesity in pregnancy has been identified by Confidential Enquiry into Maternal And Child Health (CEMACH) (2008-2011) as a major health risk to mother and baby. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-005013-11 | Sponsor Protocol Number: D2452L00007 | Start Date*: 2005-02-01 |
Sponsor Name:Umeå University Hospital | ||
Full Title: A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-p... | ||
Medical condition: The "metabolic syndrome" is a cluster of metabolic and cardiovascular risk factors. Insulin resistance appears to be a central disease mechanism and hypertension is another important component. A t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001650-26 | Sponsor Protocol Number: ZOL6700 | Start Date*: 2019-10-25 |
Sponsor Name:Hospital South West Jutland | ||
Full Title: Zoledronic acid for prevention of bone loss after bariatric surgery | ||
Medical condition: Morbid obese subjects undergoing bariatric surgery | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001356-36 | Sponsor Protocol Number: 20131 | Start Date*: 2013-10-10 | |||||||||||
Sponsor Name:"G. d'Annunzio" University | |||||||||||||
Full Title: Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell perfo... | |||||||||||||
Medical condition: Obesity with a diagnosis of impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) or type 2 Diabetes Mellitus (T2DM) for less than 12 months, according to the American Diabetes Associa... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003673-34 | Sponsor Protocol Number: BioCellThyr | Start Date*: 2018-04-05 |
Sponsor Name:Oslo University Hospital, Department of Endocrinologi, Morbid Obesity and Preventive Medicine | ||
Full Title: Identification of non-responders to levothyroxine-therapy: development of biomarkers reflecting T4 and T3 action at the tissue level | ||
Medical condition: Women with dysregulated hypothyroidism | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003853-70 | Sponsor Protocol Number: PNRR-MR1-2022-12375914 | Start Date*: 2023-05-02 | |||||||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi... | |||||||||||||||||||||||
Medical condition: Wolfram syndrome type 1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001611-37 | Sponsor Protocol Number: T2F12017 | Start Date*: 2019-02-27 |
Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III | ||
Full Title: A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men ... | ||
Medical condition: hypogonadism, T2DM, prediabetes, overweight, obesity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000197-35 | Sponsor Protocol Number: IR-HP-14-01 | Start Date*: 2015-06-09 | ||||||||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | ||||||||||||||||||
Full Title: insulin resistance, obesity and gastrointestinal bacteria | ||||||||||||||||||
Medical condition: Helicobacter pylori infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005531-28 | Sponsor Protocol Number: Urso in Obese | Start Date*: 2008-04-03 | |||||||||||
Sponsor Name:Hanns-Ulrich Marschall | |||||||||||||
Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery | |||||||||||||
Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s... | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002560-16 | Sponsor Protocol Number: 747-303 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis | |||||||||||||
Medical condition: Nonalcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Completed) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003470-47 | Sponsor Protocol Number: 74730.041.20 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:UMCU Utrecht [...] | |||||||||||||
Full Title: BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY – AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Protection Covid infection by patients with chronic diseases or major surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000399-41 | Sponsor Protocol Number: NOGGO-ov42 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:NOGGO e. V. | |||||||||||||
Full Title: Rucaparib MAintenance after Bevacizumab Maintenance following Carboplatin based first line chemotherapy in Ovarian Cancer patients | |||||||||||||
Medical condition: This is a multicenter, randomized, placebo controlled, double blind study including patients with patients with histologically confirmed, advanced (FIGO stage IIIB, IIIC, or IV of the 2014 FIGO cla... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000214-11 | Sponsor Protocol Number: RG_11-225 | Start Date*: 2013-06-18 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||||||||||||||||||||||
Full Title: BREVITY: A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity | ||||||||||||||||||||||||||||||||||||||
Medical condition: Hodgkin lymphoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
